Robustness of Serologic Investigations for Chikungunya and Mayaro Viruses following Coemergence.
Adolescent
Adult
Alphavirus
Alphavirus Infections
/ immunology
Antibodies, Viral
/ blood
Brazil
Chikungunya virus
Child
Cohort Studies
Cross Reactions
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Male
Middle Aged
Neutralization Tests
Peru
Young Adult
Brazil
ELISA
Peru
arbovirus diagnostics
cross-reactivity
mosquito-borne disease
outbreak
serology
Journal
mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533
Informations de publication
Date de publication:
05 02 2020
05 02 2020
Historique:
entrez:
7
2
2020
pubmed:
7
2
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Since 2013, the arthropod-borne Chikungunya virus (CHIKV) has cocirculated with the autochthonous Mayaro virus (MAYV) in Latin America. Both belong to the same alphavirus serocomplex, termed the Semliki Forest serocomplex. The extent of antibody cross-reactivity due to the antigenic relatedness of CHIKV and MAYV in commonly used serologic tests remains unclear. By testing 64 CHIKV- and 37 MAYV-specific sera from cohort studies conducted in Peru and Brazil, we demonstrate about 50% false-positive test results using commercially available enzyme-linked immunosorbent assays (ELISAs) based on structural antigens. In contrast, combining ELISAs for CHIKV and MAYV significantly increased positive predictive values (PPV) among all cohorts from 35.3% to 88.2% for IgM and from 61.3% to 96.8% for IgG (
Identifiants
pubmed: 32024703
pii: 5/1/e00915-19
doi: 10.1128/mSphere.00915-19
pmc: PMC7002312
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 Fischer et al.
Références
Lancet. 2014 Feb 8;383(9916):514
pubmed: 24506907
mSphere. 2018 Mar 21;3(2):
pubmed: 29577083
Antiviral Res. 2019 Dec;172:104610
pubmed: 31545981
Int J Infect Dis. 2020 Feb;91:38-43
pubmed: 31704226
Antiviral Res. 2019 Jun;166:66-81
pubmed: 30905821
Am J Trop Med Hyg. 2005 Jun;72(6):805-10
pubmed: 15964967
J Infect Dis. 1998 Mar;177(3):634-41
pubmed: 9498442
J Vet Med B Infect Dis Vet Public Health. 2003 Aug;50(6):265-9
pubmed: 14628996
Microbes Infect. 2016 Dec;18(12):724-734
pubmed: 27989728
Acta Trop. 2019 Feb;190:395-402
pubmed: 30552880
Am J Trop Med Hyg. 2019 Jun;100(6):1541-1544
pubmed: 31017081
mSphere. 2018 Jan 31;3(1):
pubmed: 29404420
J Clin Microbiol. 2019 Apr 26;57(5):
pubmed: 30787146
Emerg Infect Dis. 2014 Dec;20(12):2129-32
pubmed: 25418184
J Virol. 2001 Nov;75(21):10118-31
pubmed: 11581380
J Infect Dis. 2016 Dec 15;214(suppl 5):S471-S474
pubmed: 27920176
Emerg Infect Dis. 2019 Feb;25(2):311-315
pubmed: 30666934
Front Immunol. 2018 Feb 01;9:117
pubmed: 29449843
Cell. 2015 Nov 19;163(5):1095-1107
pubmed: 26553503
J Clin Virol. 2012 Nov;55(3):191-203
pubmed: 22840968
Virol J. 2018 Jul 24;15(1):112
pubmed: 30041676
Vaccine. 2012 Jun 29;30(31):4638-43
pubmed: 22583812
mBio. 2017 Nov 14;8(6):
pubmed: 29138300